ProKidney Corp Valuation Analysis

PROK Stock  USD 1.92  0.04  2.13%   
ProKidney Corp is priced without meaningful earnings support — a reading that maps directly to thin margins and elevated leverage. ProKidney Corp's enterprise value is currently 6.6 M. Price-to-book currently stands at 97.15.
Above Model Estimate
Today
1.92
The intrinsic value estimate for ProKidney Corp is based on a 3 months horizon. Lack of a positive P/E ratio suggests inconsistent earnings, which introduces uncertainty into valuation. Extending the time horizon generally improves valuation stability.
1.66
Intrinsic Value
6.10
Current intrinsic value estimate framed by downside and upside probability thresholds.

Valuation Framework, Methodology & Assumptions

ProKidney Corp is a small-cap equity. Profitability trends drive pricing sustainability. For ProKidney Corp, P/S of 635.71, enterprise value (TTM) of 6.64 million, P/B of 97.15 anchors the current valuation read.

Reported values for ProKidney Corp are derived from periodic company reporting and market reference feeds and standardized for analysis. Valuation outputs are model-derived and depend on published assumptions and reference inputs.

The analysis above is generated by quantitative models and is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an endorsement to buy or sell any security. All investing involves risk, including the possible loss of principal. Consult a qualified financial advisor before making investment decisions. See our Terms of Use for full details.

Financial data referenced in this analysis is derived from publicly available SEC filings, audited financial statements, and third-party market data providers. The intrinsic value estimate is generated by Macroaxis quantitative models that incorporate fundamental analysis, technical indicators, and risk metrics.

The methodology combines multiple analytical inputs:

  • Fundamental analysis - financial statements, profitability ratios, debt structure, and cash flow metrics sourced from SEC filings and public financial reports
  • Technical indicators - historical price patterns, momentum signals, and volatility measures
  • Risk assessment - probability of bankruptcy models, market risk metrics, and downside scenario analysis
  • Peer comparison - relative valuation against industry peers using standardized multiples

Model outputs are refreshed periodically as new financial data becomes available. Past model performance is not indicative of future results. The intrinsic value estimate reflects a point-in-time calculation and should be considered alongside other research and professional advice.

Data sourced from SEC filings (EDGAR), public financial statements, and market data providers.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors

More Resources for ProKidney Corp Stock Analysis

Initial analysis of ProKidney Corp centers on its financial statements and observed trends. Ratios connect earnings, costs, and operational efficiency.